In the News
Avoiding Chemo: Two Promising Drugs Go Head-to-Head in New Clinical Trial
Gateway for Cancer Research accelerates practice-changing clinical trials to cancer research by harnessing the unrelenting passion of the research community and empowering patients to triumph over their disease. All of this is guided by a clear vision: To shape a world in which a cancer diagnosis is no longer feared.
Botensilimab/Balstilimab Elicits Major Pathologic Responses in Colon Cancer
CancerNetwork reports major pathologic responses in pMMR and dMMR colon cancer with neoadjuvant botensilimab plus balstilimab in the Phase 2 NEST trial.
Speed and Rigor Are Not in Conflict
Garo Armen argues FDA Operation TrialBlazer should put patients first by speeding evidence-based access to cancer treatments without lowering standards.
Global Health Dialogues with Princess Dina and Dr. Garo Armen
Garo H. Armen, PhD, Chairman and Chief Executive Officer, Agenus and Princess Dina explore the promise and limits of immunotherapy.
The Old System Failed Patients. Change Must Go Further and Faster
Garo H. Armen, PhD, Chairman and Chief Executive Officer, Agenus provides perspectives on further changes needed to support innovations for patients
Teaching the Immune System to Remember: Exclusive Conversation with Dr. Nicholas DeVito
An in-depth profile of Dr. Nicholas DeVito on why immunotherapy should come first—exploring Bot/Bal, trial design, and how sequencing can drive durable cancer control.